Loading...
Loading...
OPTN| Name | Value |
|---|---|
| Revenues | 20.9M |
| Cost of Revenue | 3.0M |
| Gross Profit | 17.9M |
| Operating Expense | 26.2M |
| Operating I/L | -8.4M |
| Other Income/Expense | -6.8M |
| Interest Income | 0.3M |
| Pretax | -15.1M |
| Income Tax Expense | 2.2M |
| Net Income/Loss | -17.3M |
OptiNose, Inc. is a specialty pharmaceutical company that develops and commercializes products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company's flagship product, XHANCE, utilizes a proprietary exhalation delivery system to deliver a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. Additionally, it offers Onzetra Xsail, a powder EDS device, and is developing OPN-019, which combines a liquid EDS device with an antiseptic. OptiNose generates revenue through the sale and commercialization of these therapeutic products.
